Sunil Hingorani
苏尼尔·欣戈拉尼
MD, PhD
Associate Director for Basic Science; Professor of Medicine基础科学副主任；内科学教授
👥Biography 个人简介
Dr. Sunil Hingorani is a leading authority on PDAC desmoplasia at Fred Hutchinson Cancer Center. He pioneered the use of pegylated hyaluronidase (PEGPH20/HALO-109) to degrade hyaluronan-rich stroma and improve drug delivery, and developed key preclinical PDAC models to study stromal remodeling.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Stromal Barrier Disruption
Demonstrated that enzymatic hyaluronan depletion with PEGPH20 re-expands collapsed blood vessels in PDAC tumors, normalizing intratumoral pressure and restoring chemotherapy perfusion in preclinical and early clinical settings.
PDAC Preclinical Modeling
Generated and characterized the KPC-derived orthotopic and syngeneic PDAC models widely used to evaluate stromal-targeting and immunotherapy combinations.
Representative Works 代表性著作
PEGPH20 plus nab-paclitaxel/gemcitabine in high-hyaluronan PDAC: randomized phase II
Journal of Clinical Oncology (2022)
Identified HA-high patient subset with PFS benefit from PEGPH20 addition, informing biomarker-selected trial design.
Hyaluronan impairs vascular function and drug delivery in pancreatic cancer
Cancer Cell (2021)
Mechanistic study linking hyaluronan accumulation to vascular collapse and therapeutic resistance in PDAC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 苏尼尔·欣戈拉尼 的研究动态
Follow Sunil Hingorani's research updates
留下邮箱，当我们发布与 Sunil Hingorani（Fred Hutchinson Cancer Research Center / University of Washington）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment